Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Up 6.13%
As of Thursday, September 17, Telix Pharmaceuticals Limited’s TLX share price has surged by 6.13%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Commentary & Analysis
Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Down 8.18%
As of Wednesday, September 16, Telix Pharmaceuticals Limited’s TLX share price has dipped by 8.18%, which has investors questioning if this is right time to buy.Michael Rose
Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Up 8.06%
As of Tuesday, September 15, Telix Pharmaceuticals Limited’s TLX share price has surged by 8.06%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Up 10.22%
As of Tuesday, September 15, Telix Pharmaceuticals Limited’s TLX share price has surged by 10.22%, which has investors questioning if this is right time to sell.Omar Beirat
Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Up 6.95%
As of Monday, September 14, Telix Pharmaceuticals Limited’s TLX share price has surged by 6.95%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | TLX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,216.8 | $272.4 | 65% |
|
| Shares Out (Mil) | 356.9 | 54.6 | 85% |
|
| Institutional Ownership | 74.4% | 92.9% | 45% |
|
| Float (Mil) | 273.6 | 42.3 | 78% |
|
| Beta | 0.60 | 0.94 | 35% |
|
| Avg Daily Volume (000s) | 468 | 526 | 58% |
|
| Price Change (52-week) |
32.8% | 54.9% | 74% |
|
| Growth | TLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 188.8% | 14.1% | 100% |
|
| Net Income (5yr) | 27.1% | (10.1%) | 82% |
|
| EPS (5yr) | 31.1% | 15.4% | 82 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (54.4%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $891 | $37 | 49% |
|
| Net Income (TTM) (Mil) | $34 | ($43) | 52% |
|
| EPS (TTM) | $0.098 | ($1.600) | 43% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | $45 | $2 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $564 | $4 | 60% |
|
| Enterprise Value (Q1) (Mil) | $4,132 | $182 | 59% |
|
| Valuation | TLX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.68 | 2.62 | 89% |
|
| P/E | 131.6 | 19.2 | 95% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 4.2 | 1.0 | 86% |
|
| Ratios | TLX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.6% | 69.0% | 59% |
|
| Net Margin | 3.8% | (73.0%) | 44% |
|
| ROA | 2.6% | (47.7%) | 59% |
|
| ROE | 7.4% | (55.0%) | 49% |
|
| Liabilities to Assets | 64.2% | 29.3% | 59% |
|
| F-Score | 4 | 2 | 33% |
|
Passing Stock Screens
As of 9/17/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 14.4% |
| +/- S&P 500: | +6.9 |
